MRI in head and neck cancer following chemoradiotherapy: what is the optimal delay to demonstrate maximal response?

1Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Objectives: To investigate the optimal timing for post-chemoradiotherapy (CRT) reference magnetic resonance imaging (MRI) in head and neck cancer, so as to demonstrate a maximal treatment response. To assess whether this differs in human papillomavirus–related oropharyngeal cancer (HPV-OPC) and whether the MRI timing impacts on the ability to predict treatment success. Methods: Following ethical approval and informed consent, 45 patients (40 male, mean age 59.7 ± 7.9 years, 33 HPV-OPC) with stage 3 and 4 HNSCC underwent pre-treatment, 6- and 12-week post-CRT MRIs in this prospective cohort study. Primary tumour (n = 39) size, T2w morphology and diffusion weight imaging (DWI) scores, together with nodal (n = 42) size and necrotic/cystic change, were recorded. Interval imaging changes were analysed for all patients and according to HPV-OPC status. MRI descriptors and their interval changes were also compared with 2-year progression-free survival (PFS). Results: All MRI descriptors significantly changed between pre-treatment and 6-week post-treatment MRI studies (p

Cite

CITATION STYLE

APA

Connor, S. E. J., Burd, C., Sivarasan, N., & Goh, V. (2021). MRI in head and neck cancer following chemoradiotherapy: what is the optimal delay to demonstrate maximal response? European Radiology, 31(12), 9273–9286. https://doi.org/10.1007/s00330-021-07913-x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free